Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 63-72

  Liu, Xianchen ^a   Chen, Yi ^b   Faries, Douglas E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Antidepressants; Length of therapy; Major depression; Retrospective analysis; Treatment adherence

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; DULOXETINE; ESCITALOPRAM; GENERIC DRUG; HYPNOTIC AGENT; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; CHRONIC PAIN; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE PLANNING; HUMAN; HYPERSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANAGED CARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79952958594     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S17846     Document Type: Article

References (43)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
2. World Health Organization. The World Health Report 2004: Changing History, Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. World Health Organization. Geneva, Switzerland; 2004.
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
4. Stafford RS, MacDonald EA, Finkelstein SN. National Patterns of Medication Treatment for Depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry. 2001;3:232-235.
5. Caley CF, Kando JC. SSRI efficacy-finding the right dose. J Psychiatr Pract. 2002;8:33-40.
6. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006; 44:300-303.
7. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definition. Value Health. 2008;11:44-47.
8. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67:1836-1855.
9. Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm. 2008;14:426-441.
10. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55: 1128-1132.
11. Lin EH, Von Korff M, Bush T, Simon GE, Walker E, Robinson P. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67-74.
12. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy: results from a managed care administrative claims database. J Manag Care Pharm. 2005;11:145-150.
13. Nantz E, Liu-Seifert H, Skljarevski V. Predictors of premature discontinuation of treatment in multiple disease states. Patient Prefer Adherence. 2009;3:31-43.
14. Bosworth HB, Voils CI, Potter GG, Steffens DC. The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiatry. 2008;3:129-134.
15. Bulloch AG, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiatry Psychiatr Epidemiol. 2010; 45:47-56.
16. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. J Clin Psychiatry. 2001;62 Suppl 22:S34-S37.
17. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). J Affect Disord. 2008;110:84-93.
18. Lin EH, Von Korff M, Ludman EJ, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry. 2003;25: 303-310.
19. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23: 1296-1310.
20. Pompili M, Serafini G, Del Casale A, et al. Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. Expert Rev Neurother. 2009;9:985-1004.
21. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164:1189-1197.
22. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55:296-300.
23. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227.
24. Beique JC, Lavoie N, de Montigny C, Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998;349:129-132.
25. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet. 2009;373:746-758.
26. Beique JC, de Montigny C, Blier P, Debonnel G. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse. 1999;32:198-211.
27. Duloxetine hydrochloride. Prescribing information. Indianapolis, IN: Lilly USA LLC; 2009.
28. Liu, XC, Chen Y, Faries D, Miner C, Swindle R. Impact of comorbidities on antidepressant initiation: duloxetine, venlafaxine, and escitalopram versus other SSRIs. 38th American College of Clinical Pharmacology Annual Meeting; 2009 Sept 13-15; San Antonio, TX.
29. Crown WH, Finkelstein S, Berndt ER, Ling, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971.
30. Matza LS, Rajagopalan KS, Thompson CL, de Lissovoy G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry. 2005;66:1432-1440.
31. Iosifescu DV, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep. 2004;6:193-201.
32. Iosifescu DV, Clementi-Craven N, Fraguas R, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005;67:703-706.
33. Liu XC, Ye W, Watson P, Tepper P. Use of benzodiazepines, hypnotics, and anxiolytics in major depressive disorder: association with chronic pain diseases. J Nerv Ment Dis. 2010;198:544-550.
34. Ong JC, Gress JL, San Pedro-Salcedo MG, Manber R. Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. J Psychosom Res. 2009;67: 135-141.
35. Shelton C. Factors impacting the selection of antidepressant treatment in patients with major depressive disorder at risk for nonadherence. CNS Spectr. 2009;14:15-19.
36. Vaccarino AL, Sills TL, Evans KR, Kalali AH. Multiple pain complaints in patients with major depressive disorder. Psychosom Med. 2009;71: 159-162.
37. Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ. 2009;12:124-135.
38. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31:206-219.
39. Ye WY, Zhao Y, Robinson R, Swindle R. Predictors of treatment initiation with duloxetine compared with venlafaxine XR among patients with major depressive disorder in US managed-care setting. 13th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2008 May 3-7; Toronto, ON.
40. Karasu TB, Gelenberg A, Merriam AE, Wang P. American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2000;157:1-45.
41. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:725-733.
42. Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med. 2010;11:648-657.
43. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149: 734-750.